arrow
F

François-Xavier Gros

Bordeaux University Hospital
H指数:11
被引数:741

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

二线阿西美单抗 ciloleucel 在不适合移植的大B细胞淋巴瘤中的最终分析

2026-09-230
OAAI
Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

大B细胞淋巴瘤CAR T细胞疗法后的应答动力学:DESCAR-T登记研究中的LYSA研究

2026-08-210
PRE
Hemophagocytic lymphohistiocytosis-like syndrome after CD19-directed CAR T-cells for B-cell lymphoma and B-cell acute lymphoblastic leukemia: A LYSA, SFCE, and GRAALL study from the DESCAR-T registry
2026-07-280
OAAI
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group

二线CAR T细胞治疗后进展的大B细胞淋巴瘤的结局和挽救策略:LYSA小组的DESCAR-T研究

2026-05-060
OAAI
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma
2026-01-130
OAAI
Large B-cell Lymphoma: The LYSA pragmatic guidelines

弥漫大B细胞淋巴瘤:LYSA实用性指南

2025-12-030
OAAI
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis

原发性纵隔B细胞淋巴瘤患者在CAR-T细胞疗法失败后的结局与治疗模式:一项DESCAR-T分析

2025-12-010
OAAI
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

CAR T细胞疗法后侵袭性B细胞淋巴瘤的晚期复发:一项来自DESCAR-T登记研究的LYSA研究

2025-10-240
OAAI
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

TRANSCAR:CD19 CAR T细胞疗法在复发/难治性转化型惰性淋巴瘤中的真实世界疗效

2025-05-050
OAAI
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study

Glofitamab在难治性或复发性弥漫性大B细胞淋巴瘤中的应用:一项在CAR-T细胞疗法失败后的II期LYSA研究

2025-04-030
PRE
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry

复发或难治性原发纵隔B细胞淋巴瘤患者接受抗CD19 CAR-T细胞治疗的结局:CARTHYM,一项来自法国国家DESCAR-T登记研究的报告

2025-02-182
OAAI
Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

异基因干细胞移植治疗复发/难治性ALK阳性间变性大细胞淋巴瘤:一项来自Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)的研究

BLOOD
IF23.1
2024-11-050
PRE
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
2024-08-061
OAAI
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial( vol 29 , pg 2593 , 2023)

Axicabtagene ciloleucel作为不适合自体干细胞移植的大b细胞淋巴瘤的二线治疗: 一项2期试验 (第29卷,2593页,2023页)

2024-05-140
OAAI
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial (Sept, 10.1038/s41591-023-02572-5, 2023)

Axicabtagene ciloleucel作为不适合自体干细胞移植的大b细胞淋巴瘤的二线治疗: 一项2期试验 (2023,10.1038/s41591-023-02572-5,9月)

2023-10-090
OAAI
Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial
2023-09-1431
OAAI
Combined Reverse-Transcriptase Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing Analyses to Assign Unclassified BCL2/BCL6- Nonrearranged Small B-Cell Lymphoid Neoplasms as Follicular or Nodal Marginal Zone Lymphoma
2023-02-010
OAAI
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
2022-06-0924
OAAI
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
2021-08-2442
OA
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
2019-12-2389
OA